middle.news
Invion Expands Skin Cancer Trial to Basal Cell Carcinoma After Positive Safety and Efficacy Signals
10:16am on Tuesday 21st of April, 2026 AEST
•
Healthcare
Read Story
Invion Expands Skin Cancer Trial to Basal Cell Carcinoma After Positive Safety and Efficacy Signals
10:16am on Tuesday 21st of April, 2026 AEST
Key Points
Safety Review Committee approves expansion to basal cell carcinoma cohort
Second squamous cell carcinoma cohort shows lesion size reductions and no adverse effects
Basal cell carcinoma represents 80% of all skin cancers, expanding market potential
Invion to recruit new BCC patients while monitoring ongoing SCC cohort
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Invion (ASX:IVX)
OPEN ARTICLE